Tech Company Financing Transactions
Ring Therapeutics Funding Round
Altitude Life Science Ventures, Flagship Pioneering and Invus participated in a $117 million Series B funding round for Ring Therapeutics. The round was announced on 7/29/2021.
Transaction Overview
Company Name
Announced On
7/29/2021
Transaction Type
Venture Equity
Amount
$117,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds for the continued development and expansion of its novel vector Anellogy platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
620 Memorial Dr. 300
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Powering a New Era of Gene Therapy. We are developing Anellovectors, the first potentially redosable and targetable gene therapy platform, by harnessing the human commensal virome.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tuyen Ong
Vice President
Simon Delagrave
VP - R & D
Roger Hajjar
Browse more venture capital transactions:
Prev: 7/29/2021: Treeverse venture capital transaction
Next: 7/29/2021: Hightouch venture capital transaction
Share this article
Where The Data Comes From
We do our best to document funding rounds that are announced publicly. VC transactions reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs